Loading...
NPI 1649418351 · Horsham, PA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Drugscan, Inc. is a clinical medical laboratory provider located in Horsham, Pennsylvania. This profile covers 21 Medicare and 98 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Drugscan, Inc. |
| Address | 200 Precision Rd |
| City | Horsham |
| State | PA |
| ZIP | 19044 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 3, 2009 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $48.3M |
| Medicare | $2.8M |
DRUGSCAN, INC. presents as a high-volume clinical testing laboratory focused on drug screening and confirmatory analyses: its Medicare and Medicaid top codes are dominated by presumptive screening (80307) and definitive GC/LC–MS confirmation codes (G0480, G0481), which include specimen validity testing and multi-class drug panels. The code mix and descriptions point to a specialized laboratory operation built around high-throughput toxicology workflows rather than a general anatomic pathology or routine chemistry practice.
Medicare revenue is highly concentrated: the provider reports $2.8M in total Medicare revenue and its precomputed top-three Medicare codes account for 97.5% of that total, with G0480 ($1.2M, 40.7%), G0481 ($809.1K, 28.5%), and 80307 ($805.6K, 28.4%) together driving nearly all Medicare billings. This concentration indicates the provider’s Medicare business is almost entirely derived from drug testing services rather than a broad panel of lab tests.
Medicaid revenue is similarly concentrated in the same service line: DRUGSCAN reports $48.3M in total Medicaid revenue and the precomputed top-three Medicaid codes account for 89.0% of that total, led by 80307 ($22.1M, 46.2%), G0480 ($15.9M, 33.1%), and G0481 ($4.7M, 9.8%). The Medicaid book of business therefore mirrors Medicare in service focus but on a much larger scale, with presumptive and definitive drug testing comprising the vast majority of revenue.
The provider’s payer mix is heavily skewed toward Medicaid: $48.3M in Medicaid revenue versus $2.8M in Medicare, indicating Medicaid is the dominant payer by an order of magnitude and the organization operates effectively as Medicaid-centric in scale. Analysts should treat DRUGSCAN as a Medicaid-majority lab when evaluating network impact, utilization risk, or contracting leverage.
DRUGSCAN is a national outlier on Medicare for its top drug-testing codes: G0480 ranks #13 of 1590 providers (99th percentile; extreme outlier, far above typical national volume), G0481 ranks #10 of 1766 providers (99th percentile; extreme outlier), and 80307 ranks #16 of 4760 providers (100th percentile; extreme outlier). Those ranks indicate this entity is a major national player in both presumptive and confirmatory drug testing among Medicare-billing laboratories, with volumes far above typical peers.
Within Pennsylvania Medicaid, the provider is likewise dominant on core toxicology codes: 80307 ranks #3 of 210 providers in-state (99th percentile; extreme outlier, far above typical state volume), G0480 ranks #3 of 132 providers in-state (98th percentile; extreme outlier), and G0481 ranks #2 of 23 providers in-state (95th percentile; notably above typical state volume). This statewide competitive standing suggests DRUGSCAN is a key laboratory for Medicaid drug-screening services in PA.
Claim volumes on Medicaid underline the operational scale required: 80307 shows 614.3K claims and G0480 shows 323.5K claims (with G0481 at 86.6K claims), supporting $22.1M and $15.9M in revenue respectively. Those claim counts imply substantial specimen intake and high-throughput processing capacity; payers and in-state networks should expect this provider to operate at an industrial testing scale rather than a low-volume regional lab.
DRUGSCAN’s NPI has been enumerated since 2009-02-03 (~17 years ago), indicating long tenure in the billing system. Combined with persistent, concentrated revenue in drug-testing CPT/HCPCS codes across both Medicare and Medicaid, the pattern is consistent with an established specialized toxicology laboratory with sustained demand for presumptive and confirmatory drug testing services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 10,320 | $110 | $1.2M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,290 | $150 | $809.1K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 13,210 | $60 | $805.6K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 310 | $190 | $59.8K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 60 | $70 | $4.2K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 50 | $50 | $2.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 20 | $30 | $600 |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 30 | $20 | $460 |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 40 | $10 | $420 |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 50 | $10 | $410 |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0480 | 1 | 40 | 270 | $110 | $94.5K |
| U0003 | 12 | 20 | 240 | $70 | $49.9K |
| G0482 | 6 | 50 | 130 | $190 | $43.2K |
| 80307 | 1 | 100 | 300 | $60 | $42.6K |
| G0481 | 1 | 60 | 100 | $150 | $37.4K |
| U0005 | 21 | 30 | 290 | $20 | $24.7K |
| 80053 | 170 | 220 | 110 | $10 | $21.6K |
| 80061 | 161 | 180 | 100 | $10 | $20.1K |
| 82306 | 145 | 160 | 60 | $30 | $19.5K |
| 84443 | 151 | 190 | 80 | $20 | $19.4K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
98 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 614,260 | $40 | $22.1M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 323,540 | $50 | $15.9M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 86,630 | $50 | $4.7M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 28,600 | $60 | $1.8M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 16,390 | $80 | $1.2M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,610 | $70 | $398.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 17,200 | $20 | $309.5K |
| 80348 | The lab analyst measures the amount of or detects the presence of buprenorphine in a patient specimen. Buprenorphine is a drug used to treat opioid addiction, to control acute pain in individuals who… | 75,170 | $1 | $225.5K |
| 80324 | The lab analyst measures the amount of or detects the presence of one or two amphetamines, a central nervous system stimulant in a patient specimen. | 50,730 | $1 | $202.9K |
| 80323 | The lab analyst identifies and evaluates the level of alkaloid drugs in a patient specimen that are not specified elsewhere in CPT® by a different code from the class of alkaloids. | 44,330 | $1 | $177.3K |
Showing 1–10 of 98
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
98 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 20 | 710 | $80 | $1.7M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 130 | 310 | $60 | $769.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 3 | 210 | 730 | $40 | $689.7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 11 | 200 | 990 | $70 | $517.5K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 20 | 3,040 | $60 | $483.4K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 20 | 540 | $50 | $367.6K |
| 80348 | The lab analyst measures the amount of or detects the presence of buprenorphine in a patient specimen. Buprenorphine is a drug used to treat opioid addiction, to control acute pain in individuals who… | 2 | 10 | 4,750 | $1 | $133.9K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 125 | 220 | 420 | $20 | $91.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 199 | 340 | 2,320 | $10 | $88.6K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 125 | 220 | 430 | $20 | $84.7K |
Showing 1–10 of 98
Other providers in the same ZIP code as Drugscan, Inc., ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Marc Chernoff | PA | Hematology & Oncology Physician | $1.5M | $0 |
| Jason Damsker | PA | Hematology & Oncology Physician | $1.3M | $0 |
| Michael Seidman | PA | Hematology & Oncology Physician | $1.2M | $0 |
| Joseph Potz | PA | Hematology & Oncology Physician | $904.6K | $0 |
| Eric's Rx LLC | PA | Community/Retail Pharmacy | $899.9K | $0 |
| Horsham Fire Co. No. 1 | PA | Ambulance | $385.4K | $347K |
| Vamshi Mallavarapu | PA | Cardiovascular Disease Physician | $564K | $3.2K |
| Venkatesh Sundararajan | PA | Pain Medicine Physician | $498.5K | $0 |
| Bruce Klugherz | PA | Cardiovascular Disease Physician | $425.7K | $0 |
| Emanuel Kostacos | PA | Cardiovascular Disease Physician | $405.7K | $470 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.